We caught up with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the use of venglustat in the treatment of patients with Parkinson’s Disease, and the Phase 2 MOVES-PD study results.
Part 2 of our discussion can be viewed here.
The abstract entitled ‘Venglustat in Parkinson’s Disease Patients with a GBA Mutation: Results from Part 2 of the Phase 2 MOVES-PD Trial’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
- What was the rationale for the use of venglustat in the treatment of patients with Parkinson’s Disease (PD)? (0:14)
- Following the recent failure of the MOVES-PD trial, what are your thoughts on the future use of GBA-targeting treatments in PD? (1:35)
- What other novel therapeutic approaches seem promising? (4:54)
Disclosures: Tanya Simuni, MD has served as a consultant for Acadia, Denali, General Electric (GE), Neuroderm, Sanofi, Sinopia, Sunovion, Roche, Takeda, MJFF and Voyager. Dr. Simuni served on the ad board for Acadia, Denali, General Electric (GE), Sunovian, Roche. Dr. Simuni has served as a member of the scientific advisory board of Neuroderm and Sanofi. Dr. Simuni has received research funding from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, Amneal, Prevail, UCB, NINDS, MJFF, Parkinson’s Foundation.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
Share this Video
Related Videos In Parkinson's Disease
Angelo Antonini, EAN 2023: Highlights in Parkinson’s disease
touchNEUROLOGY editorial board member Prof. Angelo Antonini (Padua University Hospital, Italy) provides an overview of his top three most important updates and hot topics from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of Parkinson’s disease. He particularly focusses on new insights in early detection of the disease before motor symptoms […]
Highlights from EAN 2023!
Veronica Clark, Parkinson’s Europe: Presidential Update, and the Parkinson’s Manifesto for Europe
The European Parkinson’s Disease Association (EPDA) recently changed its name to Parkinson’s Europe. They are the only European Parkinson’s umbrella organisation and have been working with the global Parkinson’s community for nearly 30 years. As a leading voice for Parkinson’s in Europe, they provide trusted information; advance and share good practices; raise awareness and improve […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!